Treatment of limited small cell lung cancer: an old or new challenge?

    Research output: Contribution to journalReview articlepeer-review


    Purpose of review: This review highlights how progress has been made in treating limited small cell lung cancer and outlines current challenges to overcome for improved cure rates. Recent findings: There is a rationale for the tumour, node, metastasis staging system to replace the current convention of limited versus extensive stage. Positron emission tomography may aid in staging but prospective validation in larger series of patients is needed. Cisplatin and etoposide chemotherapy has yet to be superseded by either newer cytotoxic drugs or targeted agents. More progress has been made for radiotherapy but questions of optimal dose, schedule, timing and treatment volume remain unanswered. Summary: Concurrent chemoradiotherapy is associated with a one in four chance of cure. Two ongoing phase III trials have been designed to address the optimal radiotherapy regimen to combine with cisplatin and etoposide. Close collaboration between radiation and medical oncologists is needed to make further progress and to improve patient access to curative intent concurrent chemoradiotherapy regimens. © 2011 Wolters Kluwer Health | Lippincott Williams & Wilkins.
    Original languageEnglish
    Pages (from-to)158-162
    Number of pages5
    JournalCurrent opinion in oncology
    Issue number2
    Publication statusPublished - Mar 2011


    • chemotherapy
    • radiotherapy
    • review
    • small cell lung cancer
    • targeted agents

    Research Beacons, Institutes and Platforms

    • Manchester Cancer Research Centre


    Dive into the research topics of 'Treatment of limited small cell lung cancer: an old or new challenge?'. Together they form a unique fingerprint.

    Cite this